AHK-Cu (alanyl-histidyl-lysyl-copper) is a copper-complexed tripeptide that sits alongside GHK-Cu as one of two copper-peptide compounds in research-vendor catalogues. Where GHK-Cu is most-characterised in dermal-remodelling and wound-healing research, AHK-Cu is most-characterised in hair-follicle biology. This monograph lays out its chemical identity, mechanism, the published research record, and how it relates to GHK-Cu.
Chemical identity and structure.
AHK-Cu is a synthetic tripeptide composed of alanine, histidine, and lysine, complexed with a divalent copper ion (Cu²⁺) coordinated primarily through the imidazole nitrogen of histidine and the peptide backbone. The full chemical descriptor is L-alanyl-L-histidyl-L-lysine:copper(II). The copper-free tripeptide AHK exists but is rarely sold; the copper complex is the active research form. Molecular weight of the copper complex is approximately 403 g/mol. The aqueous solution carries a faint blue-green tint characteristic of copper-peptide chelates.
Mechanism of action.
AHK-Cu's research relevance derives from two mechanisms. First, the copper-coordination chemistry — copper is a cofactor for lysyl oxidase, an enzyme essential for collagen and elastin cross-linking, and for several other metalloenzymes implicated in tissue remodelling. Second, preclinical work has characterised effects on dermal-papilla-cell proliferation and VEGF expression in hair-follicle biology models, which is the mechanism most often cited in the hair-research context. Unlike GHK-Cu, AHK-Cu does not have a substantive role in wound-healing or generalised dermal-remodelling literature — its preclinical evidence base is narrower and concentrated in follicle biology.
Research applications and the evidence base.
Published preclinical research on AHK-Cu is dominated by in-vitro studies on dermal-papilla cells and VEGF-pathway activation, plus a small number of cosmetic-formulation papers describing scalp and follicle effects in topical research contexts. Completed human clinical trials of AHK-Cu as a stand-alone research compound are essentially absent; the cosmetic literature is mostly formulation chemistry rather than randomised trials. Anyone presenting AHK-Cu as a proven hair-growth therapy is overstating the underlying evidence.
Research context.
AHK-Cu and GHK-Cu are frequently discussed together but address different research questions. GHK-Cu is the broader, more-cited copper tripeptide with applications across wound healing, dermal remodelling, and inflammatory skin biology. AHK-Cu is the narrower, follicle-focused copper tripeptide. Researchers studying hair-follicle biology in particular sometimes use the two in parallel; researchers studying general dermal remodelling typically work with GHK-Cu alone.
Storage and handling.
Lyophilized AHK-Cu vials should be kept refrigerated (2–8 °C) and protected from light — copper-peptide complexes are photosensitive and oxidation-prone. The blue-green tint is normal and reflects the copper complex; loss of colour or yellowing indicates copper dissociation or oxidation and the batch should be re-checked against the COA.
Quality and COA considerations.
A meaningful COA should confirm identity via mass spectrometry against the copper-complex molecular weight, purity by HPLC (≥98% benchmark for the peptide component), and quantitative copper content — a copper-deficient AHK-Cu sample will pass HPLC purity on the peptide line but lacks the active complex. Sterility and endotoxin testing should be reported for any vial intended for injection-model use.
Research-use note: This monograph is an educational summary of the published preclinical research on AHK-Cu. The compound has not been evaluated in completed human clinical trials and is not approved for human use in any jurisdiction known to VialTalk. Nothing here is medical advice or a usage recommendation.
